Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.6 USD 5.26% Market Closed
Market Cap: 143.3m USD
Have any thoughts about
Compugen Ltd?
Write Note

Operating Margin
Compugen Ltd

17.7%
Current
-318%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.7%
=
Operating Profit
10.6m
/
Revenue
59.9m

Operating Margin Across Competitors

Country IL
Market Cap 143.3m USD
Operating Margin
18%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202.3B USD
Operating Margin
17%
Country US
Market Cap 166.6B USD
Operating Margin
21%
Country KR
Market Cap 66.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.8B USD
Operating Margin
24%
Country US
Market Cap 36.3B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 162.8B CNY
Operating Margin
27%
No Stocks Found

Compugen Ltd
Glance View

Market Cap
143.3m USD
Industry
Life Sciences Tools & Services

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

CGEN Intrinsic Value
0.84 USD
Overvaluation 47%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.7%
=
Operating Profit
10.6m
/
Revenue
59.9m
What is the Operating Margin of Compugen Ltd?

Based on Compugen Ltd's most recent financial statements, the company has Operating Margin of 17.7%.